Advanced-therapy medicinal products

  • Email
  • Help

Advanced-therapy medicinal products (ATMPs) are medicines for human use that are based on gene therapy, somatic-cell therapy or tissue engineering. They offer groundbreaking new opportunities for the treatment of disease and injury.

The regulatory framework for ATMPs is established in Regulation (EC) No 1394/2007.

These pages provide information for applicants on:

  • the classification of ATMP marketing-authorisation applications;
  • certification of the quality of ATMPs;
  • non-clinical data submitted by small and medium-sized enterprises (SMEs) developing ATMPs.

Support to companies

The Innovation Task Force (ITF) provides a forum for informal dialogue between the European Medicines Agency and companies or individuals in the early stages of the medicine development process.

In addition, the Agency can provide support to companies through:

More information

Related information